1. Introduction {#sec1-pharmacy-05-00021}
===============

A number of drugs are known to exert latent harm on pregnant women and their fetuses \[[@B1-pharmacy-05-00021]\]. According to previous studies on drug use in pregnant women, 40%--90% of these women take at least one drug \[[@B2-pharmacy-05-00021],[@B3-pharmacy-05-00021],[@B4-pharmacy-05-00021],[@B5-pharmacy-05-00021],[@B6-pharmacy-05-00021],[@B7-pharmacy-05-00021],[@B8-pharmacy-05-00021],[@B9-pharmacy-05-00021],[@B10-pharmacy-05-00021],[@B11-pharmacy-05-00021],[@B12-pharmacy-05-00021],[@B13-pharmacy-05-00021],[@B14-pharmacy-05-00021],[@B15-pharmacy-05-00021],[@B16-pharmacy-05-00021],[@B17-pharmacy-05-00021],[@B18-pharmacy-05-00021],[@B19-pharmacy-05-00021],[@B20-pharmacy-05-00021],[@B21-pharmacy-05-00021],[@B22-pharmacy-05-00021],[@B23-pharmacy-05-00021],[@B24-pharmacy-05-00021]\]. A study found that the use of a single drug acting on the central nervous system was not related to congenital abnormalities; however, the use of multiple such drugs presented a higher risk of congenital abnormalities \[[@B25-pharmacy-05-00021]\]. Therefore, it is important for surveys to be conducted on multidrug use and drug use in pregnant women.

In the Japanese health system, patients mainly obtain their prescribed drugs from community-based pharmacies, based on a prescription made by a doctor in a community clinic or hospital. Patients can also buy over-the-counter drugs in most community pharmacies. To the best of our knowledge, there has been no study based on a large-scale birth cohort survey in Japan. Therefore, there is little information about drug use and safety during pregnancy in Japan, and data from western countries have had to be used.

To elucidate the status of drug use by pregnant women, we analyzed a dataset from the Japan Environment and Children's Study, which focused on drug use before and during pregnancy in approximately 100,000 Japanese women.

2. Methods {#sec2-pharmacy-05-00021}
==========

2.1. Study Settings and Subjects {#sec2dot1-pharmacy-05-00021}
--------------------------------

In January 2011, the Japanese Ministry of Environment launched a large-scale cohort epidemiological research project entitled the Japan Environment and Children's Study (JECS) \[[@B26-pharmacy-05-00021]\]. JECS is an ongoing nationwide birth cohort study. The plan was to recruit approximately 100,000 pregnant women and their partners over a period of 3 years (i.e., 33,333 per year, which is around 3% of Japanese newborns), collect biological samples, and conduct follow-ups for their children until they reach 13 years of age. The eligibility criteria for participants (expecting mothers) were as follows: (1) They should reside in the study areas at the time of the recruitment, and would be expected to reside continually in Japan for the foreseeable future, (2) expected delivery date should be between 1 August 2011 and mid-2014, and (3) they should be capable to participate in the study without difficulty, i.e., they must be able to comprehend the Japanese language and complete the self-administered questionnaire. Those residing outside the study areas, even if they visited the cooperating health care providers within the study areas, were excluded from the study.

The JECS protocol has been published elsewhere \[[@B26-pharmacy-05-00021]\], and was approved by the Ministry of Environment's Institutional Review Board on Epidemiological Studies on 6 April 2010 (no. 100406001), as well as by the Ethics Committees for all participating institutions. Written informed consent was obtained from all participating women and their families. For the JECS, participants were recruited through the 15 Regional Centers located in Hokkaido, Miyagi, Fukushima, Chiba, Kanagawa, Koshin, Toyama, Aichi, Kyoto, Osaka, Hyogo, Tottori, Kochi, Fukuoka, and South Kyushu and Okinawa ([Figure 1](#pharmacy-05-00021-f001){ref-type="fig"}). Registration for JECS was open between January 2011 and March 2014 for pregnant women on a nationwide basis, and the required data were recorded. In total, about 100,000 pregnant women were enrolled between January 2011 and March 2014.

The expected date of delivery was determined by comparing the expected date calculated from the crown rump length (CRL) at 8--11 pregnancy weeks, and the one calculated from the last menstrual period. Also, the expected date was calculated from biparietal diameter (BPD) for participants after the correction period with the CRL (around 8--11 weeks) or whose CRL \>4 mm. In the case where there was a gap of seven or more days between the expected date of delivery calculated from the start of the last menstrual period and the one calculated from the CRL, the one calculated from the CRL value was adopted. In the case where there was a gap of 10 or more days between the expected dates of delivery as calculated from the start of the last menstrual period and the date calculated from the BPD, the one calculated from the BPD value was adopted.

The present study was based on the data set jecs-ag-20160426, which was released in June 2016. We analyzed this primary dataset from 104,102 records ([Figure 2](#pharmacy-05-00021-f002){ref-type="fig"}). The data set was created using children as the base. For example, in the case of twin pregnancies, two records (one each for the first and second child) were created for each pregnant woman. Because this study investigated pregnant women, in the case of multiple pregnancies, the records of children beyond the first child were excluded. We analyzed the data from pregnant women who had participated in both "In-T1" and "In-T2" interviews. Of 104,102 records in the jecs-ag-20160426 dataset, the records from 97,464 were analyzed.

2.2. Data Collection {#sec2dot2-pharmacy-05-00021}
--------------------

All data on drug use were obtained based on two interviews: The "In-T1" interview was performed upon enrollment for mothers during the maternal first trimester or the second trimester (see [Appendix A](#app1-pharmacy-05-00021){ref-type="app"}), and the "In-T2" interview was performed during the second or third trimester (see [Appendix B](#app2-pharmacy-05-00021){ref-type="app"}). With respect to responses to interviews regarding drug use: During "In-T1" and "In-T2", a survey was performed by research coordinators through a face-to-face interview for pregnant women, and information was collected from a set medication list (see [Appendix C](#app3-pharmacy-05-00021){ref-type="app"} for the full list).

Drug use information was collected during each of the following time periods: (1) Before pregnancy diagnosis (drug use during the 12 months before pregnancy diagnosis), (2) Before week 12 of pregnancy (drug use from pregnancy diagnosis until Week 12 of pregnancy), and (3) After week 12 of pregnancy (drug use from week 12 of pregnancy until the time of the "In-T1" or "In-T2" interview). At period (1), drug use information was collected at the "In-T1" interview. In periods (2) and (3), drug use information was collected at both the "In-T1" and "In-T2" interviews. If a response was recorded at either In-T1 or In-T2, drug use was defined as present.

The gestation week of the In-T1 and In-T2 interviews were calculated back from the date of childbirth, the date of "In-T1" and "In-T2" interview, and the gestation week of birth based on the data set jecs-ag-20160426. Because only the year and month were provided for the dates of childbirth and the dates of the "In-T1" and "In-T2" interviews, the day was defined as the first of the month in all cases.

All data for the study were obtained from the following questionnaires: The "M-T1" questionnaire was performed upon enrollment for mothers during the maternal first or second trimester (M-T1), the"M-T2" questionnaire was performed for mothers during the second or third trimester (M-T2), the "Dr-T1" medical chart review was carried out by a doctor upon enrollment (Dr-T1), and the "Dr-0m" medical chart review was carried out by a doctor immediately after delivery (Dr-0m).

2.3. Data Analysis {#sec2dot3-pharmacy-05-00021}
------------------

Based on the M-T1, Dr-T1, M-T2, and Dr-0m questionnaires, the frequency and proportion of pregnant females were calculated, with a focus on the following items: gestation (weeks) of M-T1, gestation (weeks) of M-T2, age, marital status, education, family income, body mass index, smoking, alcohol consumption, parity, fertility treatment, history of spontaneous abortion, history of mental health disorders, hypertension, diabetes, mental health disorders, other pregnancy complications, hypertensive disorders of pregnancy, gestational diabetes, and other obstetric labor complications.

We analyzed the percentages of pregnant women who had taken one or more drugs, excluding supplements such as those for iron, folic acid, and other vitamins and minerals.

All analyses were performed using SAS statistical software, Version 9.4 (SAS Institute Inc., Cary, NC, USA).

3. Results {#sec3-pharmacy-05-00021}
==========

The participants of the 15 Regional Centers of JECS are shown in [Table 1](#pharmacy-05-00021-t001){ref-type="table"}. The participants of JECS were distributed nationwide from the north, Hokkaido, to the south, Okinawa. The total number of interviewees in the JECS survey was around 130,000 pregnant women between January 2011 and March 2014, and the number of agreements was 103,099 pregnant women, so the agreement ratio was around 79%. Agreement ratios for each Regional Center have not been determined at this time. In the present analysis, the study population consisted of 104,102 pregnant women. A total of 6638 pregnant women were excluded because of overlapped records for multiple pregnancies, and incomplete "In-T1" and "In-T2" interviews. Thus, we studied 97,464 pregnant women ([Figure 2](#pharmacy-05-00021-f002){ref-type="fig"}). Characteristics of subjects are shown in [Table 2](#pharmacy-05-00021-t002){ref-type="table"}. The mean age and median gestation time of In-T1 and In-T2 in the subjects was 30.8 years, 15.7 weeks, and 27.6 weeks respectively. The median gestation time of M-T1 and M-T2 in the subjects was 15.4 weeks, and 27.7 weeks respectively.

The drugs most commonly used by the women are presented in [Table 3](#pharmacy-05-00021-t003){ref-type="table"}. The following drugs and supplements (five upstream items) were frequently used during the 12 months before pregnancy diagnosis: (1) commercially available antipyretics, analgesics, and/or medicine for treating common colds (34.68%), (2) antipyretics, analgesics, and/or medicine for treating common cold prescribed in hospitals (29.82%), (3) antimicrobial drugs (14.02%), (4) anti-allergy drugs (12.53%), and (5) Chinese herbal medicines (8.61%).

The following drugs and supplements (five upstream items) were frequently used from the time of pregnancy diagnosis until week 12 of pregnancy: (1) folic acid (28.89%), (2) antipyretics, analgesics, and/or medicine for treating common cold prescribed in hospitals (7.76%), (3) Chinese herbal medicines (6.02%), (4) uterine relaxants (5.11%), and (5) minerals (4.92%).

The following drugs and supplements (five upstream items) were frequently used from week 12 of pregnancy until the time of the "In-T2" interview: (1) folic acid (26.16%), (2) uterine relaxants (15.21%), (3) antipyretics, analgesics, and/or medicine for treating common cold prescribed in hospitals (13.32%), (4) iron preparations (12.04%), and (5) Chinese herbal medicines (9.41%).

Drug combinations are shown in [Table 4](#pharmacy-05-00021-t004){ref-type="table"}. The percentages of pregnant women that took one or more drugs before diagnosis of pregnancy, between the time of diagnosis of pregnancy until week 12 of pregnancy, and after week 12 of pregnancy, were 78.41%, 57.07%, and 68.84%, respectively. A maximum of 10 drugs were combined for the before-pregnancy diagnosis, 11 from the time period between pregnancy diagnosis until week 12 of pregnancy, and 14 for the time period after week 12 of pregnancy.

We analyzed the data, excluding data pertaining to iron supplements, folic acid, and other vitamins and minerals ([Table 5](#pharmacy-05-00021-t005){ref-type="table"}). The percentages of pregnant women who had used one or more drugs before diagnosis of pregnancy, from pregnancy diagnosis until week 12 of pregnancy, and after week 12 of pregnancy, were 75.33%, 36.02%, and 51.72%, respectively. A maximum of 10 drugs were combined for the before-pregnancy diagnosis, 10 for the time period between pregnancy diagnosis until Week 12 of pregnancy, and 12 for the time period after Week 12 of pregnancy.

4. Discussion {#sec4-pharmacy-05-00021}
=============

To the best of our knowledge, this study is the first large-scale nationwide investigation on drug use during pregnancy in Japan. Of 101,490 records in the data set, we analyzed the records of 97,464.

The percentage of pregnant women who had used one or more drugs from the time of pregnancy diagnosis until week 12 of pregnancy was 57.07%. This finding was lower than the percentages reported in studies on pregnant women who had used drugs during the first trimester in Germany (69.7%) \[[@B9-pharmacy-05-00021]\] and China (75.9%) \[[@B22-pharmacy-05-00021]\], and higher than the figures reported in studies on pregnant women who had used drugs during the first trimester in Italy (30.7%, 41.0%) \[[@B10-pharmacy-05-00021],[@B11-pharmacy-05-00021]\], The Netherlands (43.6%) \[[@B12-pharmacy-05-00021]\], and Norway (32.8%) \[[@B14-pharmacy-05-00021]\]. When we excluded iron, folic acid, and other vitamin and mineral supplements from our analysis, the percentage of drug usage from the time of pregnancy diagnosis until Week 12 of pregnancy was lowered to 36.02%. The prevalence of pregnant women who had used drugs during the first trimester in this cohort was similar to that which was reported in studies conducted in the United States (39.0%) \[[@B15-pharmacy-05-00021]\], lower than that reported in studies conducted in Germany (53.6%) \[[@B9-pharmacy-05-00021]\] and China (47.7%) \[[@B22-pharmacy-05-00021]\], and higher than that which was reported in those conducted in Denmark (21.6%) \[[@B4-pharmacy-05-00021]\]. In comparison to the findings of studies conducted in other countries, the percentage of pregnant women who had used drugs during the early pregnancy period in our cohort was moderate.

The following drugs and supplements (three upstream items) were frequently used from the time of diagnosis of pregnancy until week 12 of pregnancy: (1) folic acid (28.89%), (2) antipyretics, analgesics, and/or medicine for treating common cold prescribed in hospitals (7.76%), and (3) Chinese herbal medicines (6.02%). The following drugs and supplements (three upstream items) were frequently used from week 12 of pregnancy until the time of the "In-T2" interview (the median gestation was 27.6 weeks): (1) folic acid (26.16%), (2) uterine relaxants (15.21%), (3) antipyretics, analgesics, and/or medicines for treating the common cold as prescribed in hospitals (13.32%).

During the first trimester, the most common drugs dispensed in other countries were as follows. Germany: alimentary tract and metabolism, 45% \[[@B9-pharmacy-05-00021]\]; Italy: hematological, 15.2% \[[@B10-pharmacy-05-00021]\]; The Netherlands: folic acid, 8.4% \[[@B13-pharmacy-05-00021]\] and folic acid and derivatives, 6.1% \[[@B12-pharmacy-05-00021]\]; Norway: antibacterials for systemic use, 9.5% \[[@B14-pharmacy-05-00021]\]; Denmark: penicillin, 16% \[[@B6-pharmacy-05-00021]\]; the United States: anti-infectives, 18.3% \[[@B15-pharmacy-05-00021]\]; China: folic acid, 65% \[[@B22-pharmacy-05-00021]\].

During the second trimester, the most common drugs dispensed in other countries were as follows. Germany: alimentary tract and metabolism, 46% \[[@B9-pharmacy-05-00021]\]; Italy: hematological, 30.8% \[[@B10-pharmacy-05-00021]\]; The Netherlands: iron preparations, 30.6% \[[@B13-pharmacy-05-00021]\] and 21.0% \[[@B12-pharmacy-05-00021]\]; Norway: antibacterials for systemic use, 12.0% \[[@B14-pharmacy-05-00021]\]; Denmark: penicillin, 18% \[[@B6-pharmacy-05-00021]\]; the United States: anti-infectives, 17.2% \[[@B15-pharmacy-05-00021]\].

Regarding folic acid ingestion, 6.99% of the pregnant women in our study had consumed folic acid before diagnosis of pregnancy. From the time of diagnosis of pregnancy until week 12 of pregnancy, and from week 12 of pregnancy until the time of the "In-T2" interview, the percentages were 28.89% and 26.16%, respectively. These values before and after pregnancy diagnosis were markedly lower than those reported in the studies conducted in other countries \[[@B27-pharmacy-05-00021]\]. This indicates that Japanese women of childbearing age should be informed about the need for folic acid intake before pregnancy, to prevent neural tube defects.

The percentage of pregnant women who had received iron preparations from the time of diagnosis of pregnancy until week 12 of pregnancy was 1.71%; this increased after week 12 to 12.04%. This trend is similar but lower than the results reported in studies conducted in Germany (10%, 30%, 40%) \[[@B9-pharmacy-05-00021]\] and The Netherlands (7.7%, 30.6%, 44.6%) \[[@B13-pharmacy-05-00021]\], and 5.2%, 21.0%, and 31.5% \[[@B12-pharmacy-05-00021]\], in a cohort of women who had used drugs during the first, second, and third trimesters respectively. We presumed that the percentage of pregnant women taking iron supplements in Japan was lower than that in Germany and The Netherlands because the frequency of anemia in Japanese pregnant women is low, and treatment guidelines for the use of iron supplements vary. Further research is probably required.

The percentages of pregnant women who had taken Chinese herbal medicines during the time period from the time of diagnosis of pregnancy until week 12 of pregnancy, and after week 12 of pregnancy, were 6.02% and 9.41%; the percentages were high after diagnosis of pregnancy. However, in this survey, the term "Chinese herbal medicines" included all types of preparations, and thus the findings must be carefully interpreted. However, these percentages were similar to the level of use in China during the first trimester (10.1%) \[[@B22-pharmacy-05-00021]\]. Chinese herbal medicine contains a large number of ingredients, and there is limited information concerning its safety during pregnancy. Safety information must be made available in the future concerning the use of these preparations during pregnancy.

The percentage of pregnant women who had received uterine relaxants during the time period from the time of diagnosis of pregnancy until week 12 of pregnancy was 5.11%; this increased after week 12 of pregnancy to 15.21%. This trend was similar to that reported in the studies conducted in Italy on tocolytic drug use during the first (5.5%), second (10.4%), and third (10.9%) trimesters \[[@B10-pharmacy-05-00021]\].

The percentages of pregnant women who had used one or more drugs, excluding those pertaining to iron supplements, folic acid, and other vitamins and minerals, during the time period between the time of diagnosis of pregnancy until week 12 of pregnancy, was 36.02%. A maximum of 10 drugs were combined for the time period between diagnosis of pregnancy until week 12 of pregnancy. The percentage of pregnant women who had used four or more drugs between the time period from the time of diagnosis of pregnancy until week 12 of pregnancy was 2.35%. This finding was similar to that reported in the National Birth Defects Prevention Study (2.2%), and lower than that reported in the Slone Epidemiology Center Birth Defects Study (7.5%) conducted in the United States \[[@B24-pharmacy-05-00021]\].

5. Limitations {#sec5-pharmacy-05-00021}
==============

The subjects of this survey were limited to only pregnant women that participated in JECS voluntarily. Thus, a number of cooperative and health conscious pregnant women likely participated in the survey. Therefore, there is some selection bias here. Furthermore, the self-reporting setup may have resulted in some cases in which drug use was not reported. No validation studies were carried out to assess the accuracy of the reports of medications. Therefore, these findings must be carefully interpreted.

The "exposure time-period" from after week 12 until the "In-T2" interview was not the same for each participant, as seen from the median (IQR) on gestation of In-T2 in [Table 2](#pharmacy-05-00021-t002){ref-type="table"}, and hence, drug use data after week 12 of pregnancy may not have been complete, since some participants may have been interviewed late in the second trimester, or early in the third trimester, and thus, their drug use in the third trimester would not have been collected, or may have been underestimated. Therefore, in general, data on drug use after Week 12 of pregnancy was likely to have been underestimated in this study.

Some drug types in the dataset were not subclassified ([Appendix C](#app3-pharmacy-05-00021){ref-type="app"}). ATC code-based drug and risk classification was not conducted, unlike the surveys conducted in Europe and the United States; it may be difficult to compare our results with those of other surveys because data sources and collection methods differed.

We could not distinguish between prescription drug use and over-the-counter drug use, because our questionnaire did not completely distinguish between prescription drug use and over-the-counter drug use.

There has been no prior drug-related study based on a large-scale birth cohort survey in Japan, and these data are a valuable starting point for pregnancy management in Japan.

6. Conclusions {#sec6-pharmacy-05-00021}
==============

The analysis of a large nationwide cohort study showed that a high percentage of Japanese pregnant women were taking medicinal drugs, even when iron, folic acid, and other supplements were excluded. Further research is required to elucidate the relationship between drug use during pregnancy and birth defects in Japan.
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![Location of the 15 Regional Centers of the Japan Environment and Children\'s Study (JECS). The participants were recruited through the 15 regional centers covered by the JECS.](pharmacy-05-00021-g001){#pharmacy-05-00021-f001}

![The study analyzed 97,464 pregnant women and provided the raw data for the JECS. \* Overlapped records: In the case of multiple pregnancy, the records beyond the first child were excluded.](pharmacy-05-00021-g002){#pharmacy-05-00021-f002}

pharmacy-05-00021-t001_Table 1

###### 

Participants of the 15 Regional Centers and Core Center of the JECS.

  Unit Center                *n*      \%
  -------------------------- -------- ------
  Hokkaido                   7709     7.9
  Miyagi                     8775     9.0
  Fukushima                  12,820   13.2
  Chiba                      5461     5.6
  Kanagawa                   6288     6.5
  Koshin                     7020     7.2
  Toyama                     5326     5.5
  Aichi                      5451     5.6
  Kyoto                      3082     3.2
  Osaka                      7735     7.9
  Hyogo                      4951     5.1
  Tottori                    3007     3.1
  Kochi                      6817     7.0
  Fukuoka                    7403     7.6
  South Kyusyu and Okinawa   5619     5.8

pharmacy-05-00021-t002_Table 2

###### 

Characteristics of study subjects (*n* = 97,464).

                                                                         *n*                 \%
  ------------------------------------- -------------------------------- ------------------- ------
  Gestation (weeks) of In-T1            Median(IQR)                      15.7 (12.3--22.1)   
                                        No response                      530                 0.5
  Gestation (weeks) of In-T2            Median(IQR)                      27.6 (25.3--31.7)   
                                        No response                      526                 0.5
  Gestation (weeks) of M-T1             Mean +/− SD                      16.8 +/− 7.4        
                                        Median(IQR)                      15.4 (12.4--19.4)   
                                        No response                      859                 0.9
  Gestation (weeks) of M-T2             Mean +/− SD                      28.3 +/− 6.1        
                                        Median(IQR)                      27.7 (25.3--30.4)   
                                        No response                      913                 0.9
  Age                                   Mean +/− SD                      30.8 +/− 5.0        
                                        \<30 years                       39,460              40.5
                                        30--34 years                     33,918              34.8
                                        ≥35 years                        23,683              24.3
                                        No response                      403                 0.4
  Marital status                        Married                          92,478              94.9
                                        Single/divorced/widowed          4183                4.3
                                        No response                      803                 0.8
  Education                             Junior high/high school          35,109              36.0
                                        Technical/junior college         40,517              41.6
                                        University/graduate school       20,816              21.4
                                        No response                      1022                1.1
  Family income                         \<4,000,000 yen                  36,280              37.2
                                        ≥4,000,000 and \<6,000,000 yen   29,788              30.6
                                        ≥6,000,000 yen                   24,025              24.7
                                        No response                      7371                7.6
  Body mass index                       \<18.5 kg/m^2^                   15,595              16.0
                                        ≥18.5 and \<25 kg/m^2^           70,483              72.3
                                        ≥25 kg/m^2^                      10,301              10.6
                                        No response                      1085                1.1
  Smoking                               Nonsmokers                       56,115              57.6
                                        Ever smokers                     35,632              36.6
                                        Current smokers                  4615                4.7
                                        No response                      1102                1.1
  Alcohol consumption                   Nondrinkers                      33,461              34.3
                                        Ever drinkers                    53,612              55.0
                                        Current drinkers                 9570                9.8
                                        No response                      821                 0.8
  Parity                                Primipara                        38,397              39.4
                                        Multipara                        56,786              58.3
                                        No response                      2281                2.3
  Fertility treatment                   Yes                              6463                6.6
                                        No                               90,595              93.0
                                        No response                      406                 0.4
  History of spontaneous abortion       Yes                              18,410              18.9
                                        No                               77,476              79.5
                                        No response                      1578                1.6
  History of a mental health disorder   No                               89,531              91.9
                                        Yes                              7551                7.8
                                        No response                      382                 0.4
  Hypertension                          No                               95,766              98.3
                                        Yes                              1189                1.2
                                        No response                      509                 0.5
  Diabetes                              No                               95,909              98.4
                                        Yes                              1046                1.1
                                        No response                      509                 0.5
  Mental health disorder                No                               96,183              98.7
                                        Yes                              772                 0.8
                                        No response                      509                 0.5
  Other pregnancy complication          No                               84,305              86.5
                                        Yes                              12,650              13.0
                                        No response                      509                 0.5
  Hypertensive disorders of pregnancy   No                               93,896              96.3
                                        Mild                             2114                2.2
                                        Severe                           945                 1.0
                                        No response                      509                 0.5
  Gestational diabetes                  No                               94,302              96.8
                                        Yes                              2653                2.7
                                        No response                      509                 0.5
  Other obstetric labor complication    No                               54,648              56.1
                                        Yes                              42,307              43.4
                                        No response                      509                 0.5

In-T1: Interview within the maternal first trimester; In-T2: Interview within the second or third trimester; M-T1: Questionnaire within the maternal first trimester; M-T2: Questionnaire within the second or third trimester; IQR: Interquartile range; SD: Standard deviation.

pharmacy-05-00021-t003_Table 3

###### 

Drug use before and during pregnancy in Japan from 2011 to 2014 ( *n* =97,464).

                                                                                                                                                      Before Pregnancy Diagnosis   Before Week 12 of Pregnancy   After Week 12 of Pregnancy                    
  ----------------------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------- ----------------------------- ---------------------------- ------- -------- -------
  Antibacterial, Antiviral, Antifungal, Carcinostatic drugs   Antimicrobial                                                                           13,668                       14.02                         3223                         3.31    8415     8.63
                                                              Antiviral                                                                               3749                         3.85                          1194                         1.23    1521     1.56
                                                              Antifungal                                                                              936                          0.96                          1112                         1.14    1904     1.95
                                                              Carcinostatic                                                                           628                          0.64                          503                          0.52    65       0.07
  Corticosteroids                                             Corticosteroids: oral administration, inhalation, infusion                              3008                         3.09                          1120                         1.15    1660     1.70
                                                              Corticosteroids: external use, enema                                                    5415                         5.56                          2756                         2.83    4283     4.39
  Antipyreic, Analgesic drugs                                 Antipyretic, Analgesic, Medicine for common cold: prescription                          29,064                       29.82                         7498                         7.82    12,982   13.32
                                                              Antipyretic, Analgesic, Medicine for common cold: over the counter                      33,799                       34.68                         3035                         3.16    1162     1.19
                                                              Poultice which the analgesic is included in                                             4352                         4.47                          926                          0.97    1711     1.76
  Antirheumatic drugs                                         Immunosuppressant, Immunoregulation                                                     650                          0.67                          470                          0.48    144      0.15
                                                              Infliximab, Etanercept                                                                  42                           0.04                          20                           0.02    21       0.02
                                                              Antirheumatic drug unidentified in detail                                               14                           0.01                          4                            0.00    4        0.00
  Antiallergy drugs                                           Antiallergic drug (oral administration, inhalation, nasal drip, tape, Antihistaminic)   12,213                       12.53                         2688                         2.76    5389     5.53
  Respiratory drugs                                           β stimulative (oral administration, inhalation)                                         528                          0.54                          286                          0.29    541      0.56
                                                              Nontypable inhalant                                                                     144                          0.15                          51                           0.05    77       0.08
                                                              Antitussive, Expectorant                                                                4711                         4.83                          1362                         1.40    4131     4.24
                                                              Theophylline                                                                            346                          0.36                          88                           0.09    189      0.19
                                                              Other respiratory drug                                                                  207                          0.21                          89                           0.09    181      0.19
  Antidiabetic drugs, Antihyperlipidemic drugs                Insulin preparation                                                                     100                          0.10                          163                          0.17    289      0.30
                                                              Hypoglycemic tablet                                                                     207                          0.21                          96                           0.10    35       0.04
                                                              Antihyperlipidemic                                                                      79                           0.08                          27                           0.03    26       0.03
                                                              Antigout                                                                                9                            0.01                          2                            0.00    2        0.00
  Hormone-related drugs                                       Thyroid hormone preparation/levothyroxine sodium                                        642                          0.66                          640                          0.66    710      0.73
                                                              Antithyroid/Thiamazole                                                                  360                          0.37                          309                          0.32    311      0.32
                                                              Other hormone drugs                                                                     2245                         2.30                          966                          0.99    340      0.35
  Blood-related drugs                                         Iron preparartion                                                                       1243                         1.28                          1670                         1.71    11,736   12.04
                                                              Other blood-related                                                                     1030                         1.06                          2181                         2.24    2040     2.09
  Cardiovasucular drugs                                       Antihypertensive (including diuretic)                                                   269                          0.28                          145                          0.15    291      0.30
                                                              Pressor                                                                                 32                           0.03                          8                            0.01    18       0.02
                                                              Antiarrhythmic, Antianginal                                                             51                           0.05                          49                           0.05    68       0.07
                                                              Heart failure therapeutic                                                               3                            0.00                          2                            0.00    3        0.00
                                                              Other caridiovasucular drugs                                                            181                          0.19                          142                          0.15    167      0.17
  Gastrointestinal drugs                                      Antiulcer (Proton pump inhibitor, H2 blocker)                                           1397                         1.43                          345                          0.35    686      0.70
                                                              General gastrointestinal agents                                                         8107                         8.32                          2777                         2.85    5036     5.17
                                                              Other gastrointestinal agents                                                           2325                         2.39                          1416                         1.45    2176     2.23
  Psychoactive drugs                                          Selective serotonin reuptake inhibitors (SSRI)                                          518                          0.53                          173                          0.18    149      0.15
                                                              Antidepressant drug except the SSRI                                                     265                          0.27                          91                           0.09    79       0.08
                                                              Antianxiety                                                                             992                          1.02                          326                          0.33    372      0.38
                                                              Sleeping pill                                                                           946                          0.97                          228                          0.23    238      0.24
                                                              Antipsychotic                                                                           233                          0.24                          104                          0.11    119      0.12
                                                              Valproic acid                                                                           180                          0.18                          66                           0.07    68       0.07
                                                              Antiepileptic except the above                                                          142                          0.15                          117                          0.12    133      0.14
                                                              Lithium carbonate                                                                       30                           0.03                          3                            0.00    4        0.00
                                                              Other psychoactive drugs                                                                116                          0.12                          32                           0.03    33       0.03
  Perinatal drugs                                             Utero relaxants                                                                         522                          0.54                          4982                         5.11    14,822   15.21
                                                              Utero-tonic                                                                             795                          0.82                          188                          0.19    279      0.29
                                                              Ovulation inducing                                                                      3846                         3.95                          277                          0.28    22       0.02
                                                              Other perinatal related drugs                                                           2420                         2.48                          2672                         2.74    1964     2.02
  Other drugs                                                 Anesthetic, pain block injection                                                        932                          0.96                          112                          0.11    447      0.46
                                                              Chinese herbal medicines                                                                8389                         8.61                          5865                         6.02    9175     9.41
                                                              External application (non-identified contents)                                          4905                         5.03                          1972                         2.02    3966     4.07
                                                              Injection, Drip infusion (non-identified contents)                                      1460                         1.50                          1043                         1.07    942      0.97
                                                              Bone & Calcium metabolism                                                               93                           0.10                          95                           0.10    126      0.13
                                                              Antimigraine headache                                                                   308                          0.32                          60                           0.06    87       0.09
                                                              Muscle relaxant                                                                         269                          0.28                          23                           0.02    21       0.02
                                                              Antiemetic drug                                                                         985                          1.01                          1802                         1.85    1316     1.35
                                                              AntiParkinson                                                                           112                          0.11                          38                           0.04    12       0.01
                                                              Hemorrhoids                                                                             297                          0.30                          377                          0.39    1076     1.10
  Supplements, vitamins/minerals                              Folic acid                                                                              6810                         6.99                          28,153                       28.89   25,494   26.16
                                                              Vitamin A                                                                               122                          0.13                          70                           0.07    72       0.07
                                                              Vitamin B                                                                               2648                         2.72                          2282                         2.34    2894     2.97
                                                              Vitamin C                                                                               2794                         2.87                          1536                         1.58    1793     1.84
                                                              Vitamin D                                                                               131                          0.13                          111                          0.11    148      0.15
                                                              Vitamin E                                                                               636                          0.65                          277                          0.28    267      0.27
                                                              Mineralas                                                                               1760                         1.81                          4797                         4.92    6751     6.93
                                                              Multi vitamins supplement                                                               3766                         3.86                          2956                         3.03    3059     3.14
                                                              Total supplement                                                                        2620                         2.69                          2680                         2.75    3380     3.47
  Illegal drugs                                               Marijuana                                                                               2                            0.00                          1                            0.00    3        0.00
                                                              Psychostimulant                                                                         1                            0.00                          0                            0.00    2        0.00
                                                              Ecstasy                                                                                 0                            0.00                          0                            0.00    1        0.00
                                                              Thinner                                                                                 1                            0.00                          0                            0.00    0        0.00
                                                              Toluene                                                                                 2                            0.00                          0                            0.00    0        0.00
                                                              Other illegal drugs                                                                     2                            0.00                          1                            0.00    0        0.00
  Vaccines                                                                                                                                            1431                         1.47                          318                          0.33    897      0.92
  Drugs not included in the list mentioned above                                                                                                      5064                         5.20                          3011                         3.09    5272     5.41
  Forgot the drug name                                                                                                                                1342                         1.38                          486                          0.50    607      0.62

Before diagnosis of pregnancy: Drug use during the 12 months before diagnosis of pregnancy, Before week 12 of pregnancy: Drug use between the time from diagnosis of pregnancy until week 12 of pregnancy, After week 12 of pregnancy: Drug use from week 12 of pregnancy until the "In-T1" or "In-T2" interview.
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###### 

Percentage of pregnant women taking more than one medication including supplements, folic acid, and other vitamins and minerals (*n* = 97,464).

  Number of Items   Before Pregnancy Diagnosis   Before Week 12 of Pregnancy   After Week 12 of Pregnancy
  ----------------- ---------------------------- ----------------------------- ----------------------------
  0                 21.59                        42.93                         31.16
  1                 25.54                        27.61                         25.51
  2                 20.06                        15.46                         18.49
  3                 19.34                        9.75                          14.30
  4                 5.14                         2.60                          5.16
  5                 3.32                         0.97                          2.57
  6                 2.56                         0.43                          1.39
  7                 1.51                         0.17                          0.69
  8                 0.69                         0.06                          0.40
  9                 0.24                         0.02                          0.19
  10                0.02                         0.01                          0.08
  11                \-                           0.003                         0.03
  12                \-                           \-                            0.01
  13                \-                           \-                            0.005
  14                \-                           \-                            0.002
  [\>]{.ul}1        78.41                        57.07                         68.84
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###### 

Percentage of pregnant women taking more than one medication excluding supplements, folic acid, and other vitamins and minerals (*n* = 97,464).

  Number of Items   Before Pregnancy Diagnosis   Before Week 12 of Pregnancy   After Week 12 of Pregnancy
  ----------------- ---------------------------- ----------------------------- ----------------------------
  0                 24.67                        63.98                         48.28
  1                 28.46                        20.54                         25.22
  2                 20.71                        9.03                          13.65
  3                 15.39                        4.10                          7.52
  4                 4.50                         1.39                          2.71
  5                 2.75                         0.58                          1.32
  6                 1.80                         0.26                          0.68
  7                 1.08                         0.08                          0.35
  8                 0.50                         0.03                          0.17
  9                 0.14                         0.01                          0.07
  10                0.01                         0.005                         0.03
  11                \-                           \-                            0.01
  12                \-                           \-                            0.003
  [\>]{.ul}1        75.33                        36.02                         51.72
